Indexing disease progression at study entry with individuals at-risk for Huntington disease

Ying Zhang, Jeffrey D. Long, James A. Mills, John H. Warner, Wenjing Lu, Jane S. Paulsen

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The identification of clinical and biological markers of disease in persons at risk for Huntington disease (HD) has increased in efforts to better quantify and characterize the epoch of prodrome prior to clinical diagnosis. Such efforts are critical in the design and implementation of clinical trials for HD so that interventions can occur at a time most likely to increase neuronal survival and maximize daily functioning. A prime consideration in the examination of prodromal individuals is their proximity to diagnosis. It is necessary to quantify proximity so that individual differences in key marker variables can be properly interpreted. We take a data-driven approach to develop an index that can be viewed as a proxy for time to HD diagnosis known as the CAG-Age Product Scaled or CAPS. CAPS is an observed utility variable computed for all genetically at-risk individuals based on age at study entry and CAG repeat length. Results of a longitudinal receiver operating characteristic (ROC) analysis showed that CAPS had a relatively strong ability to predict individuals who became diagnosed, especially in the first 2 years. Bootstrap validation provided evidence that CAPS computed on a new sample from the same population could have similar discriminatory power. Cutoffs for the empirical CAPS distribution can be used to create a classification for mutation-positive individuals (Low-Med-High), which is, useful for comparison with the naturally occurring mutation-negative Control group. The classification is an improvement over the one currently in use as it is based on observed data rather than model-based estimated values.

Original languageEnglish (US)
Pages (from-to)751-763
Number of pages13
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Volume156
Issue number7
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Huntington Disease
Disease Progression
Biomarkers
Mutation
Aptitude
Proxy
Individuality
ROC Curve
Clinical Trials
Control Groups
Population

Keywords

  • PREDICT-HD study
  • Prodromal Huntington disease
  • Survival analysis

ASJC Scopus subject areas

  • Genetics(clinical)
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Indexing disease progression at study entry with individuals at-risk for Huntington disease. / Zhang, Ying; Long, Jeffrey D.; Mills, James A.; Warner, John H.; Lu, Wenjing; Paulsen, Jane S.

In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 156, No. 7, 01.12.2011, p. 751-763.

Research output: Contribution to journalArticle

Zhang, Ying ; Long, Jeffrey D. ; Mills, James A. ; Warner, John H. ; Lu, Wenjing ; Paulsen, Jane S. / Indexing disease progression at study entry with individuals at-risk for Huntington disease. In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2011 ; Vol. 156, No. 7. pp. 751-763.
@article{c12773ab7c9545bc9d532aef5ce9870b,
title = "Indexing disease progression at study entry with individuals at-risk for Huntington disease",
abstract = "The identification of clinical and biological markers of disease in persons at risk for Huntington disease (HD) has increased in efforts to better quantify and characterize the epoch of prodrome prior to clinical diagnosis. Such efforts are critical in the design and implementation of clinical trials for HD so that interventions can occur at a time most likely to increase neuronal survival and maximize daily functioning. A prime consideration in the examination of prodromal individuals is their proximity to diagnosis. It is necessary to quantify proximity so that individual differences in key marker variables can be properly interpreted. We take a data-driven approach to develop an index that can be viewed as a proxy for time to HD diagnosis known as the CAG-Age Product Scaled or CAPS. CAPS is an observed utility variable computed for all genetically at-risk individuals based on age at study entry and CAG repeat length. Results of a longitudinal receiver operating characteristic (ROC) analysis showed that CAPS had a relatively strong ability to predict individuals who became diagnosed, especially in the first 2 years. Bootstrap validation provided evidence that CAPS computed on a new sample from the same population could have similar discriminatory power. Cutoffs for the empirical CAPS distribution can be used to create a classification for mutation-positive individuals (Low-Med-High), which is, useful for comparison with the naturally occurring mutation-negative Control group. The classification is an improvement over the one currently in use as it is based on observed data rather than model-based estimated values.",
keywords = "PREDICT-HD study, Prodromal Huntington disease, Survival analysis",
author = "Ying Zhang and Long, {Jeffrey D.} and Mills, {James A.} and Warner, {John H.} and Wenjing Lu and Paulsen, {Jane S.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1002/ajmg.b.31232",
language = "English (US)",
volume = "156",
pages = "751--763",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Indexing disease progression at study entry with individuals at-risk for Huntington disease

AU - Zhang, Ying

AU - Long, Jeffrey D.

AU - Mills, James A.

AU - Warner, John H.

AU - Lu, Wenjing

AU - Paulsen, Jane S.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - The identification of clinical and biological markers of disease in persons at risk for Huntington disease (HD) has increased in efforts to better quantify and characterize the epoch of prodrome prior to clinical diagnosis. Such efforts are critical in the design and implementation of clinical trials for HD so that interventions can occur at a time most likely to increase neuronal survival and maximize daily functioning. A prime consideration in the examination of prodromal individuals is their proximity to diagnosis. It is necessary to quantify proximity so that individual differences in key marker variables can be properly interpreted. We take a data-driven approach to develop an index that can be viewed as a proxy for time to HD diagnosis known as the CAG-Age Product Scaled or CAPS. CAPS is an observed utility variable computed for all genetically at-risk individuals based on age at study entry and CAG repeat length. Results of a longitudinal receiver operating characteristic (ROC) analysis showed that CAPS had a relatively strong ability to predict individuals who became diagnosed, especially in the first 2 years. Bootstrap validation provided evidence that CAPS computed on a new sample from the same population could have similar discriminatory power. Cutoffs for the empirical CAPS distribution can be used to create a classification for mutation-positive individuals (Low-Med-High), which is, useful for comparison with the naturally occurring mutation-negative Control group. The classification is an improvement over the one currently in use as it is based on observed data rather than model-based estimated values.

AB - The identification of clinical and biological markers of disease in persons at risk for Huntington disease (HD) has increased in efforts to better quantify and characterize the epoch of prodrome prior to clinical diagnosis. Such efforts are critical in the design and implementation of clinical trials for HD so that interventions can occur at a time most likely to increase neuronal survival and maximize daily functioning. A prime consideration in the examination of prodromal individuals is their proximity to diagnosis. It is necessary to quantify proximity so that individual differences in key marker variables can be properly interpreted. We take a data-driven approach to develop an index that can be viewed as a proxy for time to HD diagnosis known as the CAG-Age Product Scaled or CAPS. CAPS is an observed utility variable computed for all genetically at-risk individuals based on age at study entry and CAG repeat length. Results of a longitudinal receiver operating characteristic (ROC) analysis showed that CAPS had a relatively strong ability to predict individuals who became diagnosed, especially in the first 2 years. Bootstrap validation provided evidence that CAPS computed on a new sample from the same population could have similar discriminatory power. Cutoffs for the empirical CAPS distribution can be used to create a classification for mutation-positive individuals (Low-Med-High), which is, useful for comparison with the naturally occurring mutation-negative Control group. The classification is an improvement over the one currently in use as it is based on observed data rather than model-based estimated values.

KW - PREDICT-HD study

KW - Prodromal Huntington disease

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=80052484592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052484592&partnerID=8YFLogxK

U2 - 10.1002/ajmg.b.31232

DO - 10.1002/ajmg.b.31232

M3 - Article

C2 - 21858921

AN - SCOPUS:80052484592

VL - 156

SP - 751

EP - 763

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 7

ER -